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Because of the sheer number of patients and 
because of their location, the community practitioner 
is in a position to deal with the vast majority of 
problems that occur in hypertension. The trend in 
hypertension therapy is toward individualizing the 
work-up of the hypertensive patient, which with 
many patients can be very simple. 
When emphasizing aspects of practical office 
care of the hypertensive, one of the first questions 
that comes to mind is: what exactly is the blood 
pressure? 
There is not any one universally accepted defini­
tion of hypertension. Until such a one is adopted, we 
have put together a Medical College of Virginia defi­
nition, using the opinions of several of us in the De­
partment of Medicine (Fig I). We use the following 
criteria: 
I. A diastolic of 95 mm Hg. Anything greater 
than this is hypertension. 
2. The seated posture. 
3. The diastolic pressure only; not the systolic 
(for reasons which will be discussed later). 
4. Disappearance of all sound (or phase V of 
Korotkoff's sounds). 
Thus, hypertension is defined as any measure­
ment that is above 95 mm Hg diastolic, in the seated 
posture. Sustained hypertension in our definition is 
three such consecutive readings, or three out of four, 
on an outpatient basis. This works out well in a prac­
tical way, because the first reading can be the "screen­
ing" blood pressure, the second one can be obtained 
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during the first evaluation of the patient, and the 
third one is taken when the lab work has come 
back. and the physician is ready to make a de­
cision about the course of treatment. Transient 
hypertension is hypertension that comes and goes, 
with normal blood pressures in between. 
There are certain simple things that should be 
done, short of long-term therapy, and these will some­
times suffice. For instance, if a patient who is grossly 
obese can be induced to lose 20% or 25% body 
weight, often there will be a drop in the blood pres­
sure. We have had very little success with this, unless 
the patient can be induced to join a group where there 
is high morale and a real motivation toward lowering 
body weight. Such a group is far superior to drug 
therapy. Another problem to be considered when 
dealing with a new hypertensive is the "cultural salt 
eater." There are some groups in the population that 
eat very salty. rich foods as a family and cultural 
tradition. Certain types of dishes extremely rich in 
salt can increase the intake to 15 to 20 gm/day. This 
can usually be discovered just by talking to the 
patient. It is not necessary to collect a 24-hour speci­
men for sodium excretion, though this would be a 
way to document it. Some of these people will have a 
mild drop in blood pressure when they are put on an 
average salt diet. This has been one of the few in­
stances where altering the salt content of the diet has 
seemed useful to us in the management of uncompli­
cated hypertension. Rarely, a patient with severe hy­
pertension can benefit from salt restriction. Some­
times, of course. it is necessary because of renal, 
hepatic, or cardiac disease. 
A few comments about contraceptive pills are in 
order. There is an average increase in the blood pres-
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HYPERTENSION: Seated diastolic blood pressure greater than 95 mm Hg in either arm. Use phase V (disappearance of Korotkolfs 
sounds). if IV and V differ by 4 rnm. record both. 
SUSTAINED HYPERTENSION: Seated blood pressure greater than 95 mm Hg diastolic on three outpatient occasions out of four at 
leasl one week apart. The pressures used may include the "screening" (or initial) pressure. 
TRANSIENT HYPERTENSION: Any seated blood pressure greater than 95 mm Hg diastolic. People with transient hypertension 
should be treated only if appropriate. or scheduled for return appointment for B.P. check in six months. 
TREATABLE HYPERTENSION: That hypertension which in the judgment of the physician carries. untreated. a greater risk than 
that of treatment. Near universal agreement now exists that seated diastolic B.P. grec1ter than 104 mm Hg (sustained) requires 
treatment in males. perhaps females too: and that greater than 95 mm Hg diastolic (sustained) requires treatment if evidence of 
cardiovascular damage is present (Grade II, III. or IV fundi. left ventricular .hypertrophy. evidence of cardiac decompensation. 
evidence of coronary artery disease). Impaired renal function. proteinuria. or hematuria are not ordinarily the result of modest 
elevation of blood pressure. Intermittent hypertension should probably also be treated if there if there is any detectable cardiovascular 
damage reasonably attributable to the blood pressure or if documented acute rises seem dangerous. 
Fig I-Definition of hypertension. as used al MCV /VCU. 
sure of young women when they take these pills, even 
in what we would call the normal population (I). The 
order of this increase is about 14 mm Hg systolic and 
8 to 9 mm Hg diastolic. It is sufficient to elevate the 
blood pressure into what we would call hypertensioil 
in a certain percentage of young women who take 
these drugs. Such patients shou Id be advised to use 
other means of contraception. This is an unusual type 
of hypertension: it builds up slowly in weeks to 
months. and it lasts from four to six months after the 
pill is discontinued. The physician cannot simply 
check the patient in two to three weeks post-pill to see 
if the high blood pressure has gone away. There is a 
subtle biochemical change in the bloodstream, in 
which the substrate for renin is actually increased. 
Renin itself may rise at first, then later fall. Of course, 
some patients are going to have to be treated. and 
then have this treatment withdrawn after four to six 
months to see if the problem has disappeared. 
Another aspect in the care of the hypertensive is 
the "treatment decision." This is the point at which 
the physician has to decide whether or not to put the 
patient on (usually) lifetime therapy. It is an impor­
tant decision because of its implications for the 
patient, having to do with self-image, the expense of 
repeated office visits, and trouble for the doctor. 
Therefore, a decision is best made with all available 
data: several blood pressures, a history, physical ex­
amination, and whatever lab work is appropriate for 
that particular patient. 
Figure 2 shows factors of importance in this deci­
sion. We feel that a patient should be treated on the 
basis of the blood pressure per se if the seated dia­
stolic blood pressure is over I 04 mm Hg. This value is 
from the Veterans Administration Cooperative Study 
(2). We should recognize that their study involved 
middle-aged men only. There were no females. The 
evidence for treatment is not quite as strong for fe­
males, but most authorities in this field feel that 
women ought to be included in this group, and that 
treatment is indicated (on blood pressure alone) 
above 104 mm Hg diastolic pressure. This may 
change as larger and larger populations are studied in 
the future. 
Below I 04 mm Hg but above 95 mm Hg, we feel 
that an individualized decision is best. Various ways 
of arriving at this have been advanced. Some physi-
TREATMENT DECISION 
Worth �arcful consideration. 
a. Risk of hypertensive complications. 
b. Cost and bother of pills and oOice visits: adverse reactions. 
2. Seated diastolic BP > 104 mm Hg (either sex), on three 
successive. or three out of four. office visits. 
J. Seated diastolic BP 95 to 104 mm HG 
PLUS 
a. Detectable CV damage. 
OR 
b. Risk factors: male sex. age under 50. black race. family 
history. high cholesterol. diabetes. cigarenes. all readings 
above 95. 
Fig 2-Factors of importance in deciding whether or not the 
patient needs treatment. 
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cians even have a "point system" that adds up 
"points" for the various factors. Such things consid­
ered are age (young), sex (male), race (black), family 
history (early occurrence of vascular diseases or hy­
pertension), increased cholesterol, and cigarette 
smoking. If cardiovascular damage can be detected 
during evaluation of the patient, the likelihood of 
further damage from hypertension is increased. Such 
damage might show up as retinal findings, on the 
electrocardiogram (left ventricular hypertrophy), and 
so forth. In short, any evidence of cardiovascular 
damage due to hypertension is thought to increase 
the patient's risk for uncontrolled hypertension and 
would be sufficient to put him in a "treatment" cate­
gory, if the diastolic is above 95 mm Hg. 
As to plasma renin, the postulate has been ad­
vanced that "low renin hypertension" carries a low 
risk. A few have even gone so far as to speculate that 
perhaps these patients should not be treated at all. 
We are not using renin for this purpose. The finding 
of "low risk" associated with "low renin hyperten­
sion" has been contradicted in a number of studies. 
and the matter is, frankly, controversial (3). 
The therapeutic aim of office management of 
chronic hypertension is reduction of the blood pres­
sure to normal. This tests the staying power of the 
doctor and patient alike as usually it involves a life­
time of therapy. 
The problem of the "missing" patient (non­
compliance) is a very difficult one and there is no 
ideal answer. We send out a lot of letters (saying. 
"where are you9") and an appointment card request­
ing the patient to come back in. A one-to-one rela­
tionship with the physician helps, and the interest the 
doctor shows in treating the blood pressure, and his 
interest in the patient, is most important. It has also 
been shown that the one-to-one relationship need not 
be with a physician (4). In large complex clinics, 
where there is a shifting physician population, it has 
been shown that a well-trained nurse (or paramedical 
personnel) can take over this role, with the physician 
then supervising the medical decisions to make sure 
that these are appropriate. In most circumstances, 
however, it is the physician who has to build this one­
to-one relationship with the patient. 
The patient ought to know the names of the 
drugs being used for treatment, their chief side ef­
fects, and the bottles ought to be labeled. This pro­
cedure is useful for most patients, although there will 
be some obvious exceptions. In terms of patient edu­
cation, there are recent efforts to produce audiovisual 
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or tape cassette aids for the patient. I have not yet 
heard of one that I thought was good enough for 
general use. Some are under development in the 
American Heart Association and will be available 
through local chapters in late 1975. A physician who 
sees a large number of hypertensive patients may 
want to tape a brief discussion of the condition for 
the benefit of new hypertensives to avoid constant 
repetition. 
A number of drugs are available to treat high 
blood pressure. Figure 3 is an attempt to subdivide 
hypertensives into levels of blood pressure severity, 
and to indicate the initial appropriate therapeutic 
regimen. We have labeled "mildest hypertension" as 
being in the range of 100 mm Hg diastolic. For this, a 
thiazide diuretic is probably the best (5). The thiazide 
diuretic dehydrates the patient very slightly, but the 
blood volume and total body water come back to 
normal after about two weeks. The patient does not 
stay dehydrated, but his blood pressure stays down. 
Fifty mg/day or twice a day or even 25 mg/day in a 
few patients can suffice (hydrochlorothiazide). There 
are some side effects that can be troublesome; hy­
pokalemia, particularly in a patient who is taking 
digitalis. A rise in the serum uric acid may occur. We 
ignore this unless it gets very high or unless a patient 
has a history of gout, in which case it is lowered with 
allopurinol. Impairment of glucose tolerance occurs 
in a certain number of patients. This may be amelio­
rated by correction of hypokalemia. Thiazides do not 
seem to cause diabetes de novo. Other diuretics have 
MILDEST HYPERTENSION: Diastolic 100 mm Hg 
Diuretic-thiazide is bcst-HCT 50 mg/day 
or b.i.d. 
MODERATELY HYPERTENSIVE: Diastolic 110 mm Hg 
Reserpine 0.1 to 0.2 mg/day 
Thiazide daily or b.i.d. 
Add hydralazine 25 to 50 mg t.i.d., if needed 
MODERATELY SEVERE: Diastolic 120 mm Hg 
Methyldopa 250 mg b.i.d. and up 
Thiazide daily or b.i.d. 
Hydralazine 25 to 50 mg t.i.d., if needed 
SEVERELY HYPERTENSIVE: Diastolic 130 mm Hg 
Thiazide daily 
Guanethidinc 25 mg (or much more) q.a.m. 
(titrate individual dose by B.P. response) 
(Later perhaps add hydralazine) 
Fig )-Drugs useful in treatment of several "grades" of hyperten­
sion. 
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hypotensive effects. but they are not as strong as the 
thiazide molecule. It does not matter which thiazide 
is used. There are about 15 of them on the market: it 
is a matter of dosage size. convenience.duration. and 
other factors. We use hydrochlorothiazide at MCV. 
For moderately hypertensive pat1ems (diastolic 
in the range of I I 0). something else is usually used in 
addition to the thiazide. The "something else" until 
recently was reserpine. We have taken all of our 
women hypertensives off reserpine. The reason is that 
several large surveys done in ew York. and repeated 
in London. have shown association between breast 
cancer and reserpine therapy. This is a bombshell: 
nobody expected it. Several people at MCV have 
been over the data and say that the studies are well 
done. We are taking it seriously. but the final resolu­
tion of this problem awaits more data. The public 
health hospitals and VA hospitals have not seen fit to 
interfere with use of reserpine for their hypertensive 
patients. but have contented themselves with sending 
out a letter to all their physicians warning them about 
this data. We use small doses of methyldopa instead 
of the reserpine. 
If something further is needed in addition to the 
small dose of reserpine or a small dose of methyl­
dopa. hydralazine is added. Hydralazine is a very 
useful drug marketed under the name of Apresoline·•. 
It is an old drug and has been around for a long time. 
It fell into disuse because of worry about a lupus 
erythematosus-like syndrome. which was quite 
serious in some patients. Studies have shown. how­
ever. that this will not occur if less than 200 mg/day is 
given to an average-size patient. Our schedule works 
out to a maximum dose of 150 mg/day. We use a lot 
of hydralazine and we have seen very little difficulty 
with it. 
Moderately severe hypertensives. with diastolic 
hypertension around 120. require methyldopa instead 
of the reserpine. The dosage has to be titrated until 
the desired response is achieved. About 3.5 gm/day 
for the average-size patient is the largest effective dos­
age in our experience. There have been some recom­
mendations in the literature for a four-times-a-day 
dosage. which is difficult for the patient to comply 
with. We have come to the conclusion that a twice-a­
day dosage is acceptable. which is important in terms 
of compliance. 
Severely hypertensive patients require our heavy 
artillery. guanethidine, marketed as lsmelin® (6). 
This is an annoying and troublesome drug to deal 
with. It interferes with sympathetic transmission in 
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the periphery and, therefore, interferes with postural 
reflexes. We have a lot of patients walking the tight­
rope between symptomatic postural hypotension 
and control of their blood pressure with guanethi­
dine. The drug takes several days to achieve its full 
effect. once given, and it takes several days to ease off 
once the dosage is decreased. It interferes with sexual 
function in males: this can be a limiting factor. Some 
men simply will not take the drug once they have had 
this experience. A physician can sometimes get by 
with less guanethidine and addition of a somewhat 
similar drug that does not have the same side effects, 
such as methyldopa. The MCV schedule says 25 mg 
"or much more." The dose of guanethidine is the 
level achieved in the individual patient after titration. 
The dosage can be as much as 250 to 300 mg/day in a 
few patients. Hydralazine can be added to this pro­
gram also and will sometimes help in the control 
without adding additional symptoms. Gastrointes­
tinal distress is a problem with guanethidine. It does 
not seem to produce any irreversible reaction in the 
G.I. tract, but it can certainly produce a symptomatic 
diarrhea that is very annoying. Lomotil® (diphenoxy­
late) is useful for this. Guanethidine can also cause 
exercise hypotension, a problem with laborers. We 
try to get by. if we can. without using large doses of 
guanethidine. There are. however. some patients who 
require it. 
Another drug just recently on the market is cloni­
dine or Catapres'-'. This drug has a mechanism of 
action similar to methyldopa, probably a central 
(brain) action that "turns down" the sympathetic sys­
tem so that it is less active. Clonidine is used similarly 
to methyldopa. We have not used much of it at MCV 
because of a pronounced "overshoot" of blood pres­
sure when it is stopped. 
A word about drug combinations. It is obvioui 
that more than one drug is often used. Drug com­
binations are useful and important because they are 
cheaper and because they simplify compliance to ther­
apy. They may present some difficulties, however. A 
well-known triple combination contains reserpine 0.1 
mg. hydralazine 25 mg, and hydrochlorothiazide 15 
mg. If this is given twice a day. an appropriate dose of 
reserpine is being given but not enough hydralazine 
or enough hydrochlorothiazide. If the frequency is 
increased to three times a day. the dosage contains a 
reasonable amount of hydralazine. but still not quite 
enough thiazide and already too much reserpine. If 
the frequency is increased yet to six times a day. 
entirely too much reserpine is being given. Most 
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patients will feel badly if they are taking that much 
reserpine. The hydralazine and hydrochlorothiazide 
are acceptable. The best way to handle combinations 
is to start the patient on individual components, see 
what he needs, and then look up the combinations 
to see if you can switch him to something that is 
cheaper and involves one less pill, in which case it is 
worth doing. 
There are a few patients who are not going to 
respond to standard therapy. A vasodilator of suf­
ficient power would decrease the blood pressure by 
increasing the size of peripheral arteries, and allowing 
the blood to circulate faster (7). When this is done, an 
increase in cardiac output occurs with an annoying 
heavy palpitation and heavy heart beat. In some in­
stances. angina pectoris occurs where it did not exist 
before. (This can be a side effect to hydralazine, for 
instance, in a patient with coronary disease). Such a 
vasodilator may also cause systemic edema, in some 
instances even heart failure, and weight gain. These 
undesirable effects can be blocked. Propranolol. (ln­
deral") will block the tachycardia. A diuretic (thiaz­
ide or furosemide) will prevent the weight gain and 
edema. This is called "triple therapy." Vasodilators 
that are more powerful than hydralazine will come on 
the market within a year or so. allowing better use of 
this triple therapy. The name of one is minoxidil. 
Propranolol must be used cautiously as it does inter­
fere with stroke volume, and it presents a significant 
danger to people with heart disease, particularly 
heart disease that has been of sufficient magnitude to 
have ever caused heart failure. This is regarded as a 
contraindication under most circumstances. Asthma 
is also a contraindication. We give propranolol in 
such a manner as to not drive the heart rate down too 
low. We like to have the heart rate remain at 60 or 
above, seated. 
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In summary, in office management of hyperten­
sion, patient education is very important; patient mo­
tivation and a strong doctor-patient relationship are 
needed. The interest and enthusiasm of the physician 
in treating blood pressure will often be the determin­
ing factor in whether or not the patient complies. 
Very simple therapy suffices for most patients. Con­
trol is possible even in most severe cases, but with 
these, considerable individualization will be needed 
and frequent office visits. 
Figun:s 1 and 2 arc reproduced with permission from the 
Virginia Medical Mo111hly ( 101:942-947, 1974). 
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